The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Nanopreparations for organelle-specific delivery in cancer
Open accessAbstract
To efficiently deliver therapeutics into cancer cells, a number of strategies have been recently investigated. The toxicity associated with the administration of chemotherapeutic drugs due to their random interactions throughout the body necessitates the development of drug-encapsulating nanopreparations that significantly mask, or reduce, the toxic side effects of the drugs. In addition to reduced side effects associated with drug encapsulation, nanocarriers preferentially accumulate in tumors as a result of its abnormally leaky vasculature via the Enhanced Permeability and Retention (EPR) effect. However, simple passive nanocarrier delivery to the tumor site is unlikely to be enough to elicit a maximum therapeutic response as the drug-loaded carriers must reach the intracellular target sites. Therefore, efficient translocation of the nanocarrier through the cell membrane is necessary for cytosolic delivery of the cargo. However, Crossing the cell membrane barrier and reaching cytosol might still not be enough for achieving maximum therapeutic benefit, which necessitates the delivery of drugs directly to intracellular targets, such as bringing pro-apoptotic drugs to mitochondria, nucleic acid therapeutics to nuclei, and lysosomal enzymes to defective lysosomes. In this review, we discuss the strategies developed for tumor targeting, cytosolic delivery via cell membrane translocation, and finally organelle-specific targeting, which may be applied for developing highly efficacious, truly multifunctional, cancer-targeted nanopreparations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–213 of 213
Ullman, E., Pan, J.-A., & Zong, W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05452-11 · Cited by 49
Toriyabe, N., Hayashi, Y., & Harashima, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.043 · Cited by 45
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
Koshkaryev, A., Thekkedath, R., Pagano, C., Meerovich, I. G., & Torchilin, V. P. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2010.550921 · Cited by 43
Self-citationImproved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes
Pappalardo, J. S., Quattrocchi, V., Langellotti, C. A., Giacomo, S. D., Gnazzo, V., Olivera, V., Calamante, G., Zamorano, P. I., Levchenko, T. S., & Torchilin, V. P. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.006 · Cited by 43
Self-citationShahzidi, S., Čunderlı́ková, B., Więdłocha, A., Zhen, Y., Vasovič, V., Nesland, J. M., & Peng, Q. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05169e · Cited by 41
Harnessing nuclear localization pathways for transgene delivery.
Bremner, K. H., Seymour, L. W., & Pouton, C. W. (2001) · PubMed · Cited by 38
Mukai, Y., Yoshinaga, T., Yoshikawa, M., Matsuo, K., Yoshikawa, T., Matsuo, K., Niki, K., Yoshioka, Y., Okada, N., & Nakagawa, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001093 · Cited by 35
Seki, T., Fang, J. Q., & Maeda, H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_3 · Cited by 33
Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Weissig, V., Boddapati, S., DʼSouza, G., & Cheng, S. H. (2004) · Drug Design Reviews - Online · doi:10.2174/1567269043480735 · Cited by 30
Vázquez, O., Blanco‐Canosa, J. B., Vázquez, M. E., Martínez-Costas, J., Castedo, L., & Mascarenas, J. L. (2008) · ChemBioChem · doi:10.1002/cbic.200800345 · Cited by 28
Yamada, Y., Nakamura, K., Furukawa, R., Kawamura, E., Moriwaki, T., Matsumoto, K., Okuda, K., Shindo, M., & Harashima, H. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23442 · Cited by 27
The intracellular and nuclear‐targeted delivery of an antiandrogen drug by carrier peptides
Hodoniczky, J., Sims, C. G., Best, W. M., Bentel, J. M., & Wilce, M. C. J. (2008) · Biopolymers · doi:10.1002/bip.20986 · Cited by 11
SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL PROPERTIES OF A FULLERENE TRIPHENYLPHOSPHONIUM SALT
Coulter, C. V., Smith, R. A. J., & Murphy, M. P. (2001) · Fullerene Science and Technology · doi:10.1081/fst-100104498 · Cited by 9
Cited by
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Nanocarriers for cancer-targeted drug delivery
Kumari, P., Ghosh, B., & Biswas, S. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1051049 · Cited by 607
Self-citationA holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Xie, J., Bi, Y., Zhang, H., Dong, S., Teng, L., Lee, R. J., & Yang, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00697 · Cited by 466
Silk fibroin nanoparticle as a novel drug delivery system
Mottaghitalab, F., Farokhi, M., Shokrgozar, M. A., Atyabi, F., & Hosseinkhani, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.020 · Cited by 444
Metadata
- Authors
- Biswas, S., & Torchilin, V. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 26-41
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2094439964
- Cited by
- 292
- References
- 213
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.